Novartis reported earnings a few days ago and the stock has held near its recent highs. The chart shows an inverse head-and-shoulders pattern, and a decisive break above resistance would trigger an upside target near $176, with a stop-loss near $151. Since its late-2024 low, the stock has rallied roughly 50%. The rising 40-week moving average and the 14-week RSI holding above 50 confirm the longer-term uptrend. Novartis is the second-largest holding in the VanEck Pharmaceutical ETF (PPH) and has outperformed it since early 2024.
Source: Read the original article
